Suppr超能文献

T管夹闭对接受霉酚酸酯口服治疗的肝移植患者霉酚酸药代动力学的影响。

Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.

作者信息

Jain A B, Hamad I, Zuckerman S, Zhang S, Warty V S, Fung J J, Venkataramanan R

机构信息

Thomas E. Starzl Transplantation Institute, School of Medicine, The University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Liver Transpl Surg. 1999 Mar;5(2):101-6. doi: 10.1002/lt.500050207.

Abstract

The aim of the study was to evaluate the effect of t-tube clamping on the pharmacokinetics of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) in primary liver transplant recipients treated with tacrolimus as the primary immunosuppressive drug. We evaluated the pharmacokinetics of MPA and its primary metabolite, mycophenolic acid glucuronide (MPAG), before and after clamping the t-tube in 8 primary liver transplant recipients treated with oral MMF and tacrolimus. The concentration of MPA and MPAG in plasma, bile, and urine samples obtained over one dosing interval was measured by high-pressure liquid chromatography. Pharmacokinetic parameters of MPA estimated before and after clamping the t-tube were compared to evaluate any significant differences at a P of.05 or less. There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%). There was also no significant difference in the ratio of the AUC of MPAG to MPA. These observations suggest that t-tube clamping does not affect the kinetics of MPA or MPAG and that no dosing alterations of MMF are required when the t-tube is clamped in liver transplant recipients.

摘要

本研究的目的是评估在以他克莫司作为主要免疫抑制药物治疗的原发性肝移植受者中,口服吗替麦考酚酯(MMF)后T管夹闭对霉酚酸(MPA)药代动力学的影响。我们评估了8例接受口服MMF和他克莫司治疗的原发性肝移植受者在T管夹闭前后MPA及其主要代谢产物霉酚酸葡糖苷酸(MPAG)的药代动力学。通过高压液相色谱法测量在一个给药间隔内采集的血浆、胆汁和尿液样本中MPA和MPAG的浓度。比较T管夹闭前后估算的MPA药代动力学参数,以评估P值为0.05或更低时是否存在任何显著差异。在达血浆峰浓度的时间(1.8±1.7对1.0±0.5小时)、MPA的血浆谷浓度(1.1±1.4对1.4±1.1微克/毫升)、MPA的血浆峰浓度(1起±7.5对11.1±4.6微克/毫升)、MPA的血浆浓度-时间曲线下面积(AUC)(40.1±31.9对43.2±21.1微克/毫升/小时)或血浆中游离或未结合MPA的百分比(3.9%±1.6%对4.1%±3.0%)方面均无显著差异。MPAG与MPA的AUC比值也无显著差异。这些观察结果表明,T管夹闭不影响MPA或MPAG的动力学,并且在肝移植受者中夹闭T管时无需调整MMF的剂量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验